The Career Developmental Program (CDP) will support early career breast cancer researchers, who have research concepts focused on the biology, prevention, diagnosis, and treatment of breast cancer. The purpose of the CDP is to help develop the careers of young investigators committed to breast cancer, and it is hoped that these funds will support the awardees? efforts to become independent researchers. The Breast SPORE will designate a minimum of $250,000 a year to the CDP, $75,000 from SPORE funds and at least $175,000 from institutional commitment. The CDP is focused on young investigators at a junior faculty level. More senior individuals who wish to change their research focus to breast cancer are encouraged to apply for the SPORE Developmental Research Program awards, not the CDP, unless they are eligible for the Special Minority Career Advancement Award. All applicants for the Career Development Awards will be required to have a faculty appointment at a DF/HCC institution participating in the SPORE; individuals in a post-doctoral fellowship program may apply if their Department Chair will guarantee a faculty appointment year should the applicant receives a CDP award. Applicants need to have a nominating letter from a faculty mentor and should detail the mentoring plan, which preferably should include a mentoring committee. Because of the need to identify and develop breast cancer researchers from minority backgrounds, we have prioritized recruitment of minorities to our CDP awards and have also created a special award exclusively for minority candidates. The annual Request for Applications will be announced by e-mail, posted throughout the DF/HCC institutions via message boards and featured on the shared DF/HCC and SPORE website. The announcement will describe the purpose of the award, provide instructions for applicants, and detail the review criteria. The requirements for mentors, review criteria and steps to monitor progress are described in this section. The CDP provided one or two-year awards for 14 faculty members in the last SPORE (2000-2010). All awardees are currently cancer researchers and most have chosen to focus their careers on breast cancer. We are confident that we can surpass this degree of success in this new SPORE application.

Public Health Relevance

The Career Development Program awards will support research projects proposed by individuals who are junior faculty members (instructor or assistant professor) or about to join the faculty. The CDP will promote the careers of junior investigators who have significant potential to contribute to breast cancer research. Since progress in breast cancer research is largely dependent on developing the next generation of breast cancer translational researchers, these awards are of considerable importance to establish a career in breast cancer research. Additionally, these projects may spawn more mature research projects whose aims are the prevention, early diagnosis or treatment of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA168504-03
Application #
8912430
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
3
Fiscal Year
2015
Total Cost
$109,135
Indirect Cost
$50,753
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Sun, Bowen; Wang, Geng; Liu, Huidong et al. (2018) Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget 9:23878-23889
Willis, Nicholas A; Panday, Arvind; Duffey, Erin E et al. (2018) Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLoS Genet 14:e1007486
Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804
Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351
Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127
Kensler, Kevin H; Beca, Francisco; Baker, Gabrielle M et al. (2018) Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. NPJ Breast Cancer 4:33
Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71
Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332
Guerriero, Jennifer L (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med 24:472-489
Kuang, Yanan; Siddiqui, Bilal; Hu, Jiani et al. (2018) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22

Showing the most recent 10 out of 66 publications